Epigenetic regulation of cell signaling pathways in acute lymphoblastic leukemia

Epigenomics

Volumn 5, Issue 5, 2013, Pages 525-538

  San Jose Eneriz, Edurne ^a   Agirre, Xabier ^a   Rodríguez Otero, Paula ^b   Prosper, Felipe ^a,b  

^a UNIVERSITY OF NAVARRA   (Spain)

^b UNIVERSITY CLINIC OF NAVARRA   (Spain)

Author keywords

acute lymphoblastic leukemia; DNA methylation; epigenetic; epigenetic therapy; histone modification

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; AMSACRINE; AZACITIDINE; BELINOSTAT; BETAMETHASONE; CP 4200; CYCLOPHOSPHAMIDE; CYTARABINE; CYTIDINE DERIVATIVE; DACINOSTAT; DOXORUBICIN; FAZARABINE; GIVINOSTAT; HYDRALAZINE; IDARUBICIN; METHOTREXATE; N PHTHALOYLTRYPTOPHAN; NSC 106084; NSC 14778; PANOBINOSTAT; PROCAINAMIDE; PROCAINE; ROMIDEPSIN; SGI 1027; SGI 110; TRICHOSTATIN A; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINCRISTINE; VORINOSTAT; ZEBULARINE; HISTONE;

ACUTE LYMPHOBLASTIC LEUKEMIA; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CARCINOGENESIS; CELL CYCLE REGULATION; DNA METHYLATION; DNA REPAIR; DNA REPLICATION; DRUG MEGADOSE; DUAL ENERGY X RAY ABSORPTIOMETRY; EPIGENETICS; GENETIC TRANSCRIPTION; GENOMIC INSTABILITY; HISTONE ACETYLATION; HISTONE METHYLATION; HUMAN; LEUKEMIA REMISSION; LEUKEMOGENESIS; MYELODYSPLASTIC SYNDROME; NONHUMAN; OVERALL SURVIVAL; PATHOGENESIS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR GENE; WNT SIGNALING PATHWAY; GENE EXPRESSION REGULATION; GENETIC EPIGENESIS; GENETICS; METABOLISM;

DNA METHYLATION; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION; HISTONES; HUMANS; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; SIGNAL TRANSDUCTION;

EID: 84884992924     PISSN: 17501911     EISSN: 1750192X     Source Type: Journal    
DOI: 10.2217/epi.13.56     Document Type: Review

References (126)

1. Jabbour EJ, Faderl S, Kantarjian HM. Adult acute lymphoblastic leukemia. Mayo Clin. Proc. 80(11), 1517-1527 (2005).
2. Pui CH, Robison L, Look AT. Acute lymphoblastic leukaemia. Lancet 371(9617), 1030-1043 (2008).
3. Faderl S, O'Brien S, Pui Ch et al. Adult acute lymphoblastic leukemia: concepts and strategies. Cancer 116(5), 1165-1176 (2010).
4. Pui CH, Evans WE. Treatment of acute lymphoblastic leukemia. N. Engl. J. Med. 354(2), 166-178 (2006).
5. Redaelli A, Laskin BL, Stephens JM, Botteman MF, Pashos CL. A systematic literature review of the clinical and epidemiological burden of acute lymphoblastic leukaemia (ALL). Eur. J. Cancer Care (Engl.) 14(1), 53-62 (2005).
6. Mullighan CG. Molecular genetics of B-precursor acute lymphoblastic leukemia. J. Clin. Invest. 122(10), 3407-3415 (2012).
7. Harrison CJ. Cytogenetics of paediatric and adolescent acute lymphoblastic leukaemia. Br. J. Haematol. 144(2), 147-156 (2009).
8. Faderl S, Jeha S, Kantarjian HM. The biology and therapy of adult acute lymphoblastic leukemia. Cancer 98(7), 1337-1354 (2003).
9. Chen J, Odenike O, Rowley JD. Leukaemogenesis: more than mutant genes. Nat. Rev. Cancer 10(1), 23-36 (2010).
10. Baylin SB, Ohm JE. Epigenetic gene silencing in cancer - a mechanism for early oncogenic pathway addiction? Nat. Rev. Cancer 6(2), 107-116 (2006).
11. Galm O, Herman JG, Baylin SB. The fundamental role of epigenetics in hematopoietic malignancies. Blood Rev. 20(1), 1-13 (2006).
12. Hatziapostolou M, Iliopoulos D. Epigenetic aberrations during oncogenesis. Cell Mol. Life Sci. 68(10), 1681-1702 (2011).
13. Stumpel DJ, Schneider P, van Roon Eh et al. Specific promoter methylation identifies different subgroups of MLL-rearranged infant acute lymphoblastic leukemia, influences clinical outcome, and provides therapeutic options. Blood 114(27), 5490-5498 (2009).
14. Davidsson J, Lilljebjorn H, Andersson A et al. The DNA methylome of pediatric acute lymphoblastic leukemia. Hum. Mol. Genet. 18(21), 4054-4065 (2009).
15. Milani L, Lundmark A, Kiialainen A et al. DNA methylation for subtype classification and prediction of treatment outcome in patients with childhood acute lymphoblastic leukemia. Blood 115(6), 1214-1225 (2010).
16. Geng H, Brennan S, Milne TA et al. Integrative epigenomic analysis identifies biomarkers and therapeutic targets in adult B-acute lymphoblastic leukemia. Cancer Discov. 2(11), 1004-1023 (2012).
17. Torano EG, Petrus S, Fernandez AF et al. Global DNA hypomethylation in cancer review of validated methods and clinical significance. Clin. Chem. Lab. Med. 50(10), 1733-1742 (2012).
18. Esteller M. The necessity of a human epigenome project. Carcinogenesis 27(6), 1121-1125 (2006).
19. Esteller M. Cancer epigenomics: DNA methylomes and histone-modification maps. Nat. Rev. Genet. 8(4), 286-298 (2007).
20. Schotte D, Lange-Turenhout EA, Stumpel DJ et al. Expression of miR-196b is not exclusively MLL-driven but is especially linked to activation of HOXA genes in pediatric acute lymphoblastic leukemia. Haematologica 95(10), 1675-1682 (2010).
21. Welch MD, Greene WK, Kees UR. Hypomethylation of the CTGF gene locus is a common feature of paediatric pre-B acute lymphoblastic leukaemia. Br. J. Haematol. 162(4), 537-541 (2013).
22. Kraszewska MD, Dawidowska M, Larmonie NS et al. DNA methylation pattern is altered in childhood T-cell acute lymphoblastic leukemia patients as compared with normal thymic subsets: insights into CpG island methylator phenotype in T-ALL. Leukemia 26(2), 367-371 (2012).
23. Kraszewska MD, Dawidowska M, Szczepanski T, Witt M. T-cell acute lymphoblastic leukaemia: recent molecular biology findings. Br. J. Haematol. 156(3), 303-315 (2012).
24. Narayan G, Freddy AJ, Xie D et al. Promoter methylation-mediated inactivation of PCDH10 in acute lymphoblastic leukemia contributes to chemotherapy resistance. Genes Chromosomes Cancer 50(12), 1043-1053 (2011).
25. Wei H, Xiang L, Wayne AS et al. Immunotoxin resistance via reversible methylation of the DPH4 promoter is a unique survival strategy. Proc. Natl Acad. Sci. USA 109(18), 6898-6903 (2012).
26. Bhatla T, Wang J, Morrison DJ et al. Epigenetic reprogramming reverses the relapse-specific gene expression signature and restores chemosensitivity in childhood B-lymphoblastic leukemia. Blood 119(22), 5201-5210 (2012).
27. Sandoval J, Heyn H, Mendez-Gonzalez J et al. Genome-wide DNA methylation profiling predicts relapse in childhood B-cell acute lymphoblastic leukaemia. Br. J. Haematol. 160(3), 406-409 (2013).
28. Dunwell T, Hesson L, Rauch TA et al. A genome-wide screen identifies frequently methylated genes in haematological and epithelial cancers. Mol. Cancer 9, 44 (2010).
29. Hutter G, Kaiser M, Neumann M et al. Epigenetic regulation of PAX5 expression in acute T-cell lymphoblastic leukemia. Leuk. Res. 35(5), 614-619 (2011).
30. Thathia SH, Ferguson S, Gautrey HE et al. Epigenetic inactivation of TWIST2 in acute lymphoblastic leukemia modulates proliferation, cell survival and chemosensitivity. Haematologica 97(3), 371-378 (2012).
31. Abd El-Hamid TM, Mossallam GI, Sherisher MA. The clinical implications of methylated p15 and p73 genes in adult acute lymphoblastic leukemia. J. Egypt Natl Canc. Inst. 22(3), 175-184 (2011).
32. Strathdee G, Holyoake TL, Sim A et al. Inactivation of HOXA genes by hypermethylation in myeloid and lymphoid malignancy is frequent and associated with poor prognosis. Clin. Cancer Res. 13(17), 5048-5055 (2007).
33. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 144(5), 646-674 (2011).
34. Davies C, Hogarth LA, Dietrich PA et al. p53-independent epigenetic repression of the p21(WAF1) gene in T-cell acute lymphoblastic leukemia. J. Biol. Chem. 286(43), 37639-37650 (2011).
35. Vilas-Zornoza A, Agirre X, Martin-Palanco V et al. Frequent and simultaneous epigenetic inactivation of TP53 pathway genes in acute lymphoblastic leukemia. PLoS One 6(2), e17012 (2011).
36. Takeuchi S, Matsushita M, Zimmermann M et al. Clinical significance of aberrant DNA methylation in childhood acute lymphoblastic leukemia. Leuk. Res. 35(10), 1345-1349 (2011).
37. Kim M, Yim SH, Cho NS et al. Homozygous deletion of CDKN2A (p16, p14) and CDKN2B (p15) genes is a poor prognostic factor in adult but not in childhood B-lineage acute lymphoblastic leukemia: a comparative deletion and hypermethylation study. Cancer Genet. Cytogenet. 195(1), 59-65 (2009).
38. Rodriguez-Otero P, Roman-Gomez J, Vilas-Zornoza A et al. Deregulation of FGFR1 and CDK6 oncogenic pathways in acute lymphoblastic leukaemia harbouring epigenetic modifications of the MIR9 family. Br. J. Haematol. 155(1), 73-83 (2011).
39. Agirre X, Vilas-Zornoza A, Jimenez-Velasco A et al. Epigenetic silencing of the tumor suppressor microRNA Hsa-miR-124a regulates CDK6 expression and confers a poor prognosis in acute lymphoblastic leukemia. Cancer Res. 69(10), 4443-4453 (2009).
40. Nordlund J, Milani L, Lundmark A, Lonnerholm G, Syvanen AC. DNA methylation analysis of bone marrow cells at diagnosis of acute lymphoblastic leukemia and at remission. PLoS One 7(4), e34513 (2012).
41. Jose-Eneriz ES, Roman-Gomez J, Cordeu L et al. BCR-ABL1-induced expression of HSPA8 promotes cell survival in chronic myeloid leukaemia. Br. J. Haematol. 142(4), 571-582 (2008).
42. Zannini L, Buscemi G, Kim JE, Fontanella E, Delia D. DBC1 phosphorylation by ATM/ ATR inhibits SIRT1 deacetylase in response to DNA damage. J. Mol. Cell Biol. 4(5), 294-303 (2012).
43. Weeks RJ, Kees UR, Song S, Morison IM. Silencing of TESTIN by dense biallelic promoter methylation is the most common molecular event in childhood acute lymphoblastic leukaemia. Mol. Cancer 9, 163 (2010).
44. Martin V, Agirre X, Jimenez-Velasco A et al. Methylation status of Wnt signaling pathway genes affects the clinical outcome of Philadelphia-positive acute lymphoblastic leukemia. Cancer Sci. 99(9), 1865-1868 (2008).
45. Zhao W, Kruse JP, Tang Y et al. Negative regulation of the deacetylase SIRT1 by DBC1. Nature 451(7178), 587-590 (2008).
46. Taylor KH, Pena-Hernandez KE, Davis JW et al. Large-scale CpG methylation analysis identifies novel candidate genes and reveals methylation hotspots in acute lymphoblastic leukemia. Cancer Res. 67(6), 2617-2625 (2007).
47. Bratton SB, Salvesen GS. Regulation of the Apaf-1-caspase-9 apoptosome. J. Cell Sci. 123, 3209-3214 (2010).
48. Forcet C, Ye X, Granger L et al. The dependence receptor DCC (deleted in colorectal cancer) defines an alternative mechanism for caspase activation. Proc. Natl Acad. Sci. USA 98(6), 3416-3421 (2001).
49. Sullivan A, Lu X. ASPP: a new family of oncogenes and tumour suppressor genes. Br. J. Cancer 96(2), 196-200 (2007).
50. Hesson LB, Dunwell TL, Cooper WN et al. The novel RASSF6 and RASSF10 candidate tumour suppressor genes are frequently epigenetically inactivated in childhood leukaemias. Mol. Cancer 8, 42 (2009).
51. Ikeda M, Hirabayashi S, Fujiwara N et al. Ras-association domain family protein 6 induces apoptosis via both caspase-dependent and caspase-independent pathways. Exp. Cell Res. 313(7), 1484-1495 (2007).
52. Kuang SQ, Bai H, Fang ZH et al. Aberrant DNA methylation and epigenetic inactivation of Eph receptor tyrosine kinases and ephrin ligands in acute lymphoblastic leukemia. Blood 115(12), 2412-2419 (2010).
53. Kuang SQ, Tong WG, Yang H et al. Genome-wide identification of aberrantly methylated promoter associated CpG islands in acute lymphocytic leukemia. Leukemia 22(8), 1529-1538 (2008).
54. Wong KY, Yim RL, Kwong YL et al. Epigenetic inactivation of the MIR129-2 in hematological malignancies. J. Hematol. Oncol. 6, 16 (2013).
55. Paulsson K, An Q, Moorman AV et al. Methylation of tumour suppressor gene promoters in the presence and absence of transcriptional silencing in high hyperdiploid acute lymphoblastic leukaemia. Br. J. Haematol. 144(6), 838-847 (2009).
56. Hoshino K, Quintas-Cardama A, Yang H, Sanchez-Gonzalez B, Garcia-Manero R. Aberrant DNA methylation of the Src kinase Hck, but not of Lyn, in Philadelphia chromosome negative acute lymphocytic leukemia. Leukemia 21(5), 906-911 (2007).
57. Agirre X, Novo FJ, Calasanz MJ et al. TP53 is frequently altered by methylation, mutation, and/or deletion in acute lymphoblastic leukaemia. Mol. Carcinog. 38(4), 201-208 (2003).
58. Niehrs C. The complex world of WNT receptor signalling. Nat. Rev. Mol. Cell Biol. 13(12), 767-779 (2012).
59. Clevers H, Nusse R. Wnt/beta-catenin signaling and disease. Cell 149(6), 1192-1205 (2012).
60. Pasquale EB. Eph receptors and ephrins in cancer: bidirectional signalling and beyond. Nat. Rev. Cancer 10(3), 165-180 (2010).
61. Chi P, Allis CD, Wang GG. Covalent histone modifications - miswritten, misinterpreted and mis-erased in human cancers. Nat. Rev. Cancer 10(7), 457-469 (2010).
62. Kouzarides T. Chromatin modifications and their function. Cell 128(4), 693-705 (2007).
63. Islam AB, Richter WF, Jacobs LA, Lopez-Bigas N, Benevolenskaya EV. Co-regulation of histone-modifying enzymes in cancer. PLoS One 6(8), e24023 (2011).
64. Florean C, Schnekenburger M, Grandjenette C, Dicato M, Diederich M. Epigenomics of leukemia: from mechanisms to therapeutic applications. Epigenomics 3(5), 581-609 (2011).
65. Lane AA, Chabner BA. Histone deacetylase inhibitors in cancer therapy. J. Clin. Oncol. 27(32), 5459-5468 (2009).
66. Kim DH, Kim M, Kwon HJ. Histone deacetylase in carcinogenesis and its inhibitors as anti-cancer agents. J. Biochem. Mol. Biol. 36(1), 110-119 (2003).
67. Witt O, Deubzer HE, Milde T, Oehme I. HDAC family: what are the cancer relevant targets? Cancer Lett. 277(1), 8-21 (2009).
68. Moreno DA, Scrideli CA, Cortez MA et al. Differential expression of HDAC3, HDAC7 and HDAC9 is associated with prognosis and survival in childhood acute lymphoblastic leukaemia. Br. J. Haematol. 150(6), 665-673 (2010).
69. Tao YF, Pang L, Du XJ et al. Differential mRNA expression levels of human histone-modifying enzymes in normal karyotype B cell pediatric acute lymphoblastic leukemia. Int. J. Mol. Sci. 14(2), 3376-3394 (2013).
70. Sonnemann J, Gruhn B, Wittig S, Becker S, Beck JF. Increased activity of histone deacetylases in childhood acute lymphoblastic leukaemia and acute myeloid leukaemia: support for histone deacetylase inhibitors as antileukaemic agents. Br. J. Haematol. 158(5), 664-666 (2012).
71. Advani AS, Gibson SE, Douglas E et al. Histone H4 acetylation by immunohistochemistry and prognosis in newly diagnosed adult acute lymphoblastic leukemia (ALL) patients. BMC Cancer 10, 387 (2010).
72. Advani AS, Gibson S, Douglas E et al. Histone H4 acetylation by immunohistochemistry and prognosis in relapsed acute lymphocytic leukaemia (ALL). Br. J. Haematol. 153(4), 504-507 (2011).
73. Noh JH, Jung KH, Kim JK et al. Aberrant regulation of HDAC2 mediates proliferation of hepatocellular carcinoma cells by deregulating expression of G1/S cell cycle proteins. PLoS One 6(11), e28103 (2011).
74. Jung KH, Noh JH, Kim JK et al. HDAC2 overexpression confers oncogenic potential to human lung cancer cells by deregulating expression of apoptosis and cell cycle proteins. J. Cell. Biochem. 113(6), 2167-2177 (2012).
75. Li N, Tie XJ, Liu PJ et al. Effects of down-regulation of HDAC6 expression on proliferation, cell cycling and migration of esophageal squamous cell carcinoma cells and related molecular mechanisms. Asian Pac. J. Cancer Prev. 14(2), 685-689 (2013).
76. Ding G, Liu HD, Huang Q et al. HDAC6 promotes hepatocellular carcinoma progression by inhibiting P53 transcriptional activity. FEBS Lett. 587(7), 880-886 (2013).
77. Zhu C, Chen Q, Xie Z et al. The role of histone deacetylase 7 (HDAC7) in cancer cell proliferation: regulation on c-Myc. J. Mol. Med. (Berl.) 89(3), 279-289 (2011).
78. Holmlund T, Lindberg MJ, Grander D, Wallberg AE. GCN5 acetylates and regulates the stability of the oncoprotein E2A-PBX1 in acute lymphoblastic leukemia. Leukemia 27(3), 578-585 (2012).
79. Mullighan CG, Zhang J, Kasper LH et al. CREBBP mutations in relapsed acute lymphoblastic leukaemia. Nature 471(7337), 235-239 (2011).
80. Inthal A, Zeitlhofer P, Zeginigg M et al. CREBBP HAT domain mutations prevail in relapse cases of high hyperdiploid childhood acute lymphoblastic leukemia. Leukemia 26(8), 1797-1803 (2012).
81. Zhang J, Ding L, Holmfeldt L et al. The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. Nature 481(7380), 157-163 (2012).
82. Varier RA, Timmers HT. Histone lysine methylation and demethylation pathways in cancer. Biochim. Biophys. Acta 1815(1), 75-89 (2010).
83. Popovic R, Shah MY, Licht JD. Epigenetic therapy of hematological malignancies: where are we now? Ther. Adv. Hematol. 4(2), 81-91 (2013).
84. Slany RK. The molecular biology of mixed lineage leukemia. Haematologica 94(7), 984-993 (2009).
85. Chen J, Li J, Han Q et al. Enhancer of zeste homolog 2 is overexpressed and contributes to epigenetic inactivation of p21 and phosphatase and tensin homolog in B-cell acute lymphoblastic leukemia. Exp. Biol. Med. (Maywood) 237(9), 1110-1116 (2012).
86. Sasaki D, Imaizumi Y, Hasegawa H et al. Overexpression of Enhancer of zeste homolog 2 with trimethylation of lysine 27 on histone H3 in adult T-cell leukemia/lymphoma as a target for epigenetic therapy. Haematologica 96(5), 712-719 (2011).
87. Mar BG, Bullinger L, Basu E et al. Sequencing histone-modifying enzymes identifies UTX mutations in acute lymphoblastic leukemia. Leukemia 26(8), 1881-1883 (2012).
88. Simon C, Chagraoui J, Krosl J et al. A key role for EZH2 and associated genes in mouse and human adult T-cell acute leukemia. Genes Dev. 26(7), 651-656 (2012).
89. Ntziachristos P, Tsirigos A, Van Vlierberghe P et al. Genetic inactivation of the polycomb repressive complex 2 in T cell acute lymphoblastic leukemia. Nat. Med. 18(2), 298-301 (2012).
90. Shimura H, Mori N, Wang YH, Okada M, Motoji T. Aberrant methylation and decreased expression of the RIZ1 gene are frequent in adult acute lymphoblastic leukemia of T-cell phenotype. Leuk. Lymphoma 53(8), 1599-1609 (2012).
91. Tan J, Yang X, Zhuang L et al. Pharmacologic disruption of Polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells. Genes Dev. 21(9), 1050-1063 (2007).
92. Konze KD, Ma A, Li F et al. An orally bioavailable chemical probe of the lysine methyltransferases EZH2 and EZH1. ACS Chem. Biol. 8(6), 1324-1334 (2013).
93. Lipka DB, Kuck D, Kliem C, Gerhauser C. Substituted purine and 7-deazapurine compounds as modulators of epigenetic enzymes: a patent evaluation (WO2012075381). Expert Opin. Ther. Pat. 23(4), 537-543 (2013).
94. Yu W, Smil D, Li F et al. Bromo-deaza-SAH: a potent and selective DOT1L inhibitor. Bioorg. Med. Chem. 21(7), 1787-1794 (2013).
95. Greiner D, Bonaldi T, Eskeland R, Roemer E, Imhof A. Identification of a specific inhibitor of the histone methyltransferase SU(VAR)3-9. Nat. Chem. Biol. 1(3), 143-145 (2005).
96. Mimasu S, Umezawa N, Sato S, Higuchi T, Umehara T, Yokoyama S. Structurally designed trans-2-phenylcyclopropylamine derivatives potently inhibit histone demethylase LSD1/KDM1. Biochemistry 49(30), 6494-6503 (2010).
97. Binda C, Valente S, Romanenghi M et al. Biochemical, structural, and biological evaluation of tranylcypromine derivatives as inhibitors of histone demethylases LSD1 and LSD2. J. Am. Chem. Soc. 132(19), 6827-6833 (2010).
98. Ueda R, Suzuki T, Mino K et al. Identification of cell-active lysine specific demethylase 1-selective inhibitors. J. Am. Chem. Soc. 131(48), 17536-17537 (2009).
99. Hamada S, Suzuki T, Mino K et al. Design, synthesis, enzyme-inhibitory activity, and effect on human cancer cells of a novel series of jumonji domain-containing protein 2 histone demethylase inhibitors. J. Med. Chem. 53(15), 5629-5638 (2010).
100. Rose NR, Woon EC, Kingham GL et al. Selective inhibitors of the JMJD2 histone demethylases: combined nondenaturing mass spectrometric screening and crystallographic approaches. J. Med. Chem. 53(4), 1810-1818 (2010).
101. Bowers EM, Yan G, Mukherjee C et al. Virtual ligand screening of the p300/CBP histone acetyltransferase: identification of a selective small molecule inhibitor. Chem. Biol. 17(5), 471-482 (2010).
102. Ott M, Verdin E. HAT trick: p300, small molecule, inhibitor. Chem. Biol. 17(5), 417-418 (2010).
103. Foulks JM, Parnell KM, Nix RN et al. Epigenetic drug discovery: targeting DNA methyltransferases. J. Biomol. Screen. 17(1), 2-17 (2011).
104. Scholz B, Marschalek R. Epigenetics and blood disorders. Br. J. Haematol. 158(3), 307-322 (2012).
105. Stumpel DJ, Schneider P, Seslija L et al. Connectivity mapping identifies HDAC inhibitors for the treatment of t(4;11)-positive infant acute lymphoblastic leukemia. Leukemia 26(4), 682-692 (2011).
106. Brueckner B, Rius M, Markelova MR et al. Delivery of 5-azacytidine to human cancer cells by elaidic acid esterification increases therapeutic drug efficacy. Mol. Cancer Ther. 9(5), 1256-1264 (2010).
107. Willemze R, Suciu S, Archimbaud E et al. A randomized Phase II study on the effects of 5-Aza-2́-deoxycytidine combined with either amsacrine or idarubicin in patients with relapsed acute leukemia: an EORTC Leukemia Cooperative Group Phase II study (06893). Leukemia 11(Suppl. 1) S24-S27 (1997).
108. Wilhelm M, O'Brien S, Rios MB et al. Phase I study of arabinosyl-5-azacytidine (fazarabine) in adult acute leukemia and chronic myelogenous leukemia in blastic phase. Leuk. Lymphoma 34(5-6), 511-518 (1999).
109. Yanez L, Bermudez A, Richard C, Bureo E, Iriondo A. Successful induction therapy with decitabine in refractory childhood acute lymphoblastic leukemia. Leukemia 23(7), 1342-1343 (2009).
110. Gryder BE, Sodji QH, Oyelere AK. Targeted cancer therapy: giving histone deacetylase inhibitors all they need to succeed. Future Med. Chem. 4(4), 505-524 (2012).
111. Dokmanovic M, Clarke C, Marks PA. Histone deacetylase inhibitors: overview and perspectives. Mol. Cancer Res. 5(10), 981-989 (2007).
112. Nebbioso A, Carafa V, Benedetti R, Altucci L. Trials with 'epigenetic' drugs: an update. Mol. Oncol. 6(6), 657-682 (2012).
113. Vilas-Zornoza A, Agirre X, Abizanda G et al. Preclinical activity of LBH589 alone or in combination with chemotherapy in a xenogeneic mouse model of human acute lymphoblastic leukemia. Leukemia 26(7), 1517-1526 (2012).
114. Kircher B, Schumacher P, Petzer A et al. Anti-leukemic activity of valproic acid and imatinib mesylate on human Ph+ ALL and CML cells in vitro. Eur. J. Haematol. 83(1), 48-56 (2009).
115. Einsiedel HG, Kawan L, Eckert C et al. Histone deacetylase inhibitors have antitumor activity in two NOD/SCID mouse models of B-cell precursor childhood acute lymphoblastic leukemia. Leukemia 20(8), 1435-1436 (2006).
116. Tsapis M, Lieb M, Manzo F et al. HDAC inhibitors induce apoptosis in glucocorticoid-resistant acute lymphatic leukemia cells despite a switch from the extrinsic to the intrinsic death pathway. Int. J. Biochem. Cell Biol. 39(7-8), 1500-1509 (2007).
117. Scuto A, Kirschbaum M, Kowolik C et al. The novel histone deacetylase inhibitor, LBH589, induces expression of DNA damage response genes and apoptosis in Ph-acute lymphoblastic leukemia cells. Blood 111(10), 5093-5100 (2008).
118. Bastian L, Hof J, Pfau M et al. Synergistic activity of bortezomib and HDACi in preclinical models of B-cell precursor acute lymphoblastic leukemia via modulation of p53, PI3K/AKT, and NF-kappaB. Clin. Cancer Res. 19(6), 1445-1457 (2013).
119. Nguyen T, Dai Y, Attkisson E et al. HDAC inhibitors potentiate the activity of the BCR/ ABL kinase inhibitor KW-2449 in imatinib-sensitive or -resistant BCR/ABL+ leukemia cells in vitro and in vivo. Clin. Cancer Res. 17(10), 3219-3232 (2011).
120. Okabe S, Tauchi T, Ohyashiki K. Efficacy of MK-0457 and in combination with vorinostat against Philadelphia chromosome positive acute lymphoblastic leukemia cells. Ann. Hematol. 89(11), 1081-1087 (2010).
121. Keshelava N, Houghton PJ, Morton CL et al. Initial testing (stage 1) of vorinostat (SAHA) by the pediatric preclinical testing program. Pediatr. Blood Cancer 53(3), 505-508 (2009).
122. Giles F, Fischer T, Cortes J et al. A Phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies. Clin. Cancer Res. 12(15), 4628-4635 (2006).
123. Garcia-Manero G, Yang H, Bueso-Ramos C et al. Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes. Blood 111(3), 1060-1066 (2008).
124. Lee-Sherick AB, Linger RM, Gore L, Keating AK, Graham DK. Targeting paediatric acute lymphoblastic leukaemia: novel therapies currently in development. Br. J. Haematol. 151(4), 295-311 (2010).
125. Lee L, Fielding AK. Emerging pharmacotherapies for adult patients with acute lymphoblastic leukemia. Clin. Med. Insights Oncol. 6, 85-100 (2012).
126. Choudhuri S. Waddington's epigenetic landscape to small noncoding RNA: some important milestones in the history of epigenetics research. Toxicol. Mech. Methods 21(4), 252-257 (2011).